Arboine-Aguirre LA, Galván-García JE, Palacios-Rodríguez JM, Guzmán-Ramírez D

Idioma: Español
Referencias bibliográficas: 30
Paginas: 320-326
Archivo PDF: 201.82 Kb.

RESUMEN

Introducción: El significado de la elevación de la troponina I (Tn-I) después de una intervención coronaria percutánea (ICP) es tema de debate. Objetivo: Determinar el pronóstico cardiovascular a un año asociado con el incremento de Tn-I posterior a ICP electiva exitosa. Método: Estudio observacional, retrospectivo y longitudinal. Se incluyeron pacientes sometidos a ICP electiva exitosa. Se dividieron en dos grupos: con y sin elevación de Tn-I, para comparar la ocurrencia de eventos cardiacos adversos mayores (ECAM) a un año; la Tn-I pos-ICP se correlacionó con características demográficas y angiográficas. Resultados: Se detectó elevación de Tn-I en 32 pacientes (35.2 %). La elevación fue más frecuente en pacientes con enfermedad coronaria multivascular, más compleja y con complicaciones peri-ICP. Los ECAM a un año fueron mayores en el grupo de Tn-I elevada (25 versus 3.4 %, p = 0.002). Los predictores independientes de ECAM fueron elevación cinco veces de Tn-I al valor normal (RM = 7.5, IC 95 % = 1.25-45, p = 0.027) y las complicaciones peri-ICP (RM = 7.5, IC 95 % = 1.25-45, p = 0.027). Conclusión: En pacientes con enfermedad coronaria estable, la elevación de Tn-I posterior a ICP electiva se asoció con eventos cardiacos adversos a un año, complicaciones peri-ICP y enfermedad coronaria más extensa y compleja.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Sánchez-Barriga JJ. Comportamiento de la mortalidad por cardiopatía isquémica en México en el periodo 2000-2007. Gac Med Mex. 2009;145:375-382.

2. García-Castillo A, Jerjes-Sánchez C, Martínez-Bermúdez P, Azpiri- López R, Autrey-Caballero A, Martínez-Sánchez C, et al. RENASICA II. Registro Mexicano de Síndromes Coronarios Agudos. Arch Cardiol Mex. 2005;75:S6-S19.

3. Chávez-Domínguez R, Ramírez-Hernández JA, Casanova-Garcés JM. La cardiopatía coronaria en México y su importancia clínica, epidemiológica y preventiva. Arch Cardiol Mex. 2003;73:105-114.

4. Murray CJ, López AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504.

5. Cavallini C, Savonitto S, Violini R, Arraiz G, Plebani M, Olivari Z, et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J. 2005;26:1494-1498.

6. Michaels AD, Chatterjee K. angioplasty versus bypass surgery for coronary artery disease. Circulation. 2002;106:e187-e190.

7. De-Labriolle A, Lemesle G, Bonello L, Syed AI, Collins SD, Ben-Dor I, et al. Prognostic significance of small troponin I rise after a successful elective percutaneous coronary intervention of a native artery. Am J Cardiol. 2009;103:639-645.

8. Bertinchant JP, Polge A, Ledermann B, Genet L, Fabbro-Peray P, Raczka F, et al. relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. Am J Cardiol. 1999;84:51-57.

9. Cavallini C, Verdecchia P, Savonitto S, Arraiz G, Violini R, Olivari Z, et al. Prognostic value of isolated troponin I elevation after percutaneous coronary intervention. Circ Cardiovasc Interv. 2010;3:431-435.

10. Zhang M, He H, Wang ZM, Xu Z, Zhou N, Chen B, et al. Diagnostic and prognostic value of minor elevated cardiac troponin levels for percutaneous coronary intervention-related myocardial injury: a prospective, single-center and double-blind study. J Biomed Res. 2014;28:98-107.

11. Nienhuis MB, Ottervanger JP, Bilo HJ, Dikkeschei BD, Zijlstra F. Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovas Interv. 2008;71:318-324.

12. Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation. 2005;111:1027-1032.

13. Ricciardi MJ, Wu E, Davidson C, Choi K, Klocke F, Bonow R, et al. Visualization of discrete microinfarction after percutaneous coronary interventions associated with mild creatine kinase-MB elevation. Circulation. 2001;103:2780-2783.

14. Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Satler LF, et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: intravascular ultrasound study of 2256 patients. Circulation. 2000;101:604-610.

15. Gómez-Hospital JA, Cequier A, Valero J, González-Costello J, Mañas P, Pascual M, et al. El daño miocárdico mínimo durante el intervencionismo coronario percutáneo no influye en el pronóstico a largo plazo. Rev Esp Cardiol. 2009;62:625-632.

16. Okmen E, Cam E, Sanli A, Unal S, Tartan Z, Vural M. Cardiac troponin I increase after successful percutaneous coronary angiopiasty: predictors and long-term prognostic value. Angiology. 2006;57(2):161-169.

17. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551-2567.

18. Nienhuis MB, Ottervanger JP, Dikkeschei B, Suryapranata H, De- Boer MJ, Dambrink JH, et al. Prognostic importance of troponin T and creatine kinase after elective angioplasty. Int J Cardiol. 2007;120: 242-247.

19. Miller WL, Garratt KN, Burritt MF, Lennon RJ, Reeder GS, Jaffe AS. Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. Eur Heart J. 2006;27:1061-1069.

20. Ricciardi MJ, Davidson CJ, Gubernikoff G, Beohar N, Eckman LJ, Parker MA, et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J. 2003;145:522-528.

21. Nienhuis MB, Ottervanger JP, Dambrink JH, Dikkeschei LD, Suryapranata H, Hoorntje JC, et al. Troponin T elevation and prognosis after multivessel compared with single-vessel elective percutaneous coronary intervention. Neth Heart J. 2007;15:178-183.

22. Califf RM, Abdelmequid AE, Kuntz RE, Pompa JJ, Davidson CJ, Cohen EA, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-251.

23. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol. 1999;33:88-96.

24. Simoons ML, Van-Den-Brand M, Lincoff M, Harrington M, Van-Der-Wieken R, Vahanian A, et al. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J. 1999;20:1112-1119.

25. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol. 1991;17:621-626.

26. Kugelmass AD, Cohen CJ, Moscucci M, Piana RN, Senerchia C, Kuntz RE, et al. Elevation of creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol. 1994;74:748-754.

27. Kini A, Marmur JD, Kini S, Dangas G, Cocke T, Wallenstein S, et al. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course: implications for early discharge after coronary intervention. J Am Coll Cardiol. 1999;34:663-671.

28. Nageh T, Sherwood RA, Harris BM, Thomas MR. Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease. Heart. 2005;91:1181-1185.

29. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di-Sciascio G, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation. 2004;110:674-678.

30. EPISTENT Investigators. Randomized placebo-controlled and balloon- angioplasty–controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352: 87-92.